FDA disease claim criteria citing "recognizable" symptoms "ambiguous," Shaklee says.
This article was originally published in The Tan Sheet
Executive Summary
FDA DISEASE CLAIM CRITERIA CITING "RECOGNIZABLE" SYMPTOMS "AMBIGUOUS" and create a "moving target" for defining acceptable structure/function claims for dietary supplements versus unacceptable disease claims, Shaklee maintains in Aug. 18 comments to the agency. The company took issue with the agency's tentative criteria that a statement would be considered a disease claim if it "explicitly or implicitly claimed an effect (using scientific or lay terminology) on one or more signs or symptoms that are recognizable to health care professionals or consumers as being characteristic of a specific disease or a number of diseases."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning